Medical documents written for doctors.
Not for the 1 in 2 patients who don't understand them.
MediClear uses AI to change that — in seconds.
Healthcare's most expensive bug isn't clinical. It's linguistic.
of patients read medication leaflets
leave hospital not understanding discharge instructions
lost annually to preventable readmissions
Point. Scan. Understand.
Any medical document, translated into language a real person can act on.
Dx: Acute exacerbation of COPD, hx pneumonia, HTN.
Continue Amoxicillin 500mg TID x7d. Titrate lisinopril per BP. F/U w/ PCP in 7-10d. PRN SABA q4-6h. Return to ED if SpO2 < 92% or worsening dyspnea.
Signed: Dr. R. Cohen, MD. Attending Pulmonology.
🫁 You have a lung infection that is getting better.
💊 Take one antibiotic pill 3 times a day for 7 days. Don't skip.
🩺 See your family doctor in 1 week.
🚨 Go back to the hospital if it becomes hard to breathe.
"Any document. Any language. 10 seconds."
Built for the patients healthcare forgets to write for.
People with autism
Predictable structure, literal language, visual cues. No hidden meaning to decode.
Elderly patients
Large type, plain words, one instruction at a time. Designed to be read alone.
Non-native speakers
Instant translation into the language they think in — not the one on the form.
Distributed by the system that already pays for the problem.
The consumer product is the wedge. The data engine is the business.
Every scan, every dose, every reminder generates a proprietary event — prescription, dispensing, consumption, reorder. De-identified and aggregated, that stream becomes population-level evidence, sold back to the industry that needs it most.
Pharmaceutical Companies
Market research and real-world evidence for existing drugs — commercial campaigns built on adherence data no claims database can produce. The global RWE market is growing to $7.4B by 2035¹, and large pharma already spends roughly $20M a year generating it in-house².
Health Funds / HMOs
Population health management and cost modeling for non-adherence — the same four health funds already paying for the patient-facing product, inside a market now worth $103.6B globally³.
The Chief Pharmacist
The economic buyer inside both. Owns medication policy and adherence outcomes — the person who actually signs off on adopting a new data source.
Every simplified prescription, every logged dose, every missed reminder becomes population-level evidence no one else can produce.
Comprehension → Adherence. No one else owns both sides.
Claims databases already have adherence data. What they don't have is comprehension — whether a patient actually understood their instructions. MediClear owns both the document-simplification layer and the adherence-tracking layer under one system, so it's the only place that can show whether understanding predicts whether a patient takes the medication. No claims database or EHR vendor can produce that correlation alone.
What lets a Chief Pharmacist say yes.
Shipped, validated, and on the map.
- MVP live
- Product & UX validated with Krembo Wings — not yet clinical evidence
- Academic advisor: Prof. Shira Chaimovitz, Ono Academic College
- Next: clinical pilot on a hospital discharge ward
Operators who have lived this problem — not observed it.
Asi Meir
20 years in special education + accessibility. Founder of Mantis Zero studio, shipping inclusive apps.
Noam Arbel
BSc, Technion — graduated with honors. Owns the AI simplification pipeline.
Prof. Shira Chaimovitz
Dean, Institute for Cognitive Accessibility, Ono Academic College.
Raising $150K — our first institutional round.
With your $150K + the Israeli government's 60-cent match — we deploy $240K to build, hire, and close our first HMO pilot.
The Israeli government co-invests alongside you — 60 cents for every dollar. They don't take equity.
$150K from you. $90K from Israel's Innovation Authority. $240K deployed.
What 10% is worth at exit.
| Exit | 10% worth |
|---|---|
| $5M | $500K |
| $10M | $1M |
| $50M | $5M |
| $100M | $10M |